Could poop pills help fight a rare liver disease?
NCT ID NCT07477782
First seen Mar 20, 2026 · Last updated Jun 20, 2026 · Updated 12 times
Summary
This study tests whether transplanting healthy donor stool into the gut can improve liver function in people with primary sclerosing cholangitis (PSC), a rare liver disease often linked to inflammatory bowel disease. 72 adults with both conditions will receive either fecal transplants or a sham procedure via colonoscopy and capsules. The main goal is to see if this approach lowers certain liver enzymes and bilirubin after 48 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hepatology Department, Saint Antoine Hospital
Paris, 75012, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fecal microbiota transplantation (FMT)
What this could lead to
If successful, this could point toward a new way to slow liver damage in PSC by restoring gut bacteria balance.
What could go wrong
This is an early phase 2 trial with only 72 people. The treatment may not work better than placebo, and there are risks from the colonoscopy procedure and swallowing capsules.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.